Update on the management of hypertension

Cardiovascular Reviews and Reports

Volumn 19, Issue 7, 1998, Pages 44-54

  Ali, Syed S ^a   Sowers, James R ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; THIAZIDE DIURETIC AGENT; VERAPAMIL;

DIABETES MELLITUS; DRUG CONTRAINDICATION; HUMAN; HYPERTENSION; KINESIOTHERAPY; LOW FAT DIET; PREVALENCE; REVIEW; SODIUM RESTRICTION; VASCULAR RESISTANCE; WEIGHT REDUCTION;

EID: 0031822719     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. Hypertension. 1994;23:275-285.
2. Stuck SE, Sin AL, Wieland GD, et al. Comprehensive geriatric assessment. A meta-analysis of controlled trials. Lancet. 1993;342:1032-1036.
3. Campion EW. The value of geriatric interventions. N Engl J Med. 1995;332:1376-1378.
4. Kannel WB, Gordon T: Evaluation of cardiovascular risk in the elderly: The Framingham study. Bull NY Acad Med. 1978;54:573-591.
5. Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in the elderly: The Framingham study. J Hypertens. 1988;6(suppl I):S3-S9.
6. Whelton PK, Klag MJ: Epidemiology of high blood pressure. Clin Geriatr Med. 1989;5:639-655.
7. Sowers JR, Khoury S, Imam K, et al. Therapeutic approach to hypertension in the elderly. Primary Care. 1991;18:593-604
8. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med. 1997;157:2413-2446.
9. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
10. Weinberger MH. Hypertension in the elderly. Hosṗ Pract. 1992;5:103-120.
11. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension. 1989;13(suppl I):I-2-I-12.
12. Perry HM, Smith WM, McDonald RH, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke. 1989;20:4-13.
13. Kuramato K, Matsushito S, Kuwajimi I. The pathogenetic role of elderly hypertension. Jpn Circ J 1981;45:833-843.
14. Madhavan S, Ooi WL, Cohen H, et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401.
15. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM. (eds). Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press; 1990:81-100.
16. Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265:2037-2048.
17. Sowers JR, Farrow SL. Treatment of elderly hypertensive patients with diabetes, renal disease, and coronary heart disease. Am J Geriatr Cordiol. 1996;5:57-70
18. Khoury S, Yarows S, O'Brien T, et al. Ambulatory blood pressure monitoring in a nonacademic setting: Effects of age and sex. Am J Hypertens 1992;5:616-623.
19. White WB, Berson AS, Robbins C, et al. National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers. Hypertension 1993;21:504-509.
20. Applegate WB, Davis BR, Black HR, et al. Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. J Am Geriatr Soc. 1991;39:1057-1064.
21. Sowers JR. Hypertension in the elderly. Am J Med. 1987;82:1-8.
22. Sowers JR, Mohanty PK. Effects of advancing age on cardiopulmonary baroreceptor function in hypertensive men. Hypertension. 1987;10:274-279.
23. Sowers JR, Mohanty PK. Norepinephrine and forearm vascular resistance responses to tilt and cold pressor test in essential hypertension: Effects of aging. Angiology. 1989;40(10):872-879.
24. Shimada K, Kitazumi T, Sadakane N, et al. Age-related changes of baroreflex function. plasma norepinephrine, and blood pressure. Hypertension. 1985;7:113-117.
25. Ooi WL, Barrett S, Hossain M, et al. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population JAMA. 1997;277:1299-1304.
26. Setaro JK, Black HR. Refractory hypertension. N Engl J Med. 1992;327:513-547.
27. Messerli KFH, Ventura HO, Aniodes C. Osler's maneuver and pseudohvpertension. N Engl J Med. 1985;312:1548-1551.
28. Amerv A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.
29. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. Br Med J. 1992;304:405-412.
30. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Prevention of stroke by antihy-pertensive drug treatment in older persons with isolated systolic hypertension: Final results of SHEP. JAMA. 1991;265:3255-3264.
31. Dahlof B, Lindholm LH, Hannson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
32. Coope J, Warrender TS. Randomized trial of treatment of hypertension in the elderly in primary care. Br Med J. 1986;293:1145.
33. Staessen JA, Fagard R, Thijs L, et al for the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997;360:757-764.
34. National Heart, Lung, and Blood Institute. Fact Book Fiscal Year 1996 Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 1997.
35. U.S. Renal Data System. USRDS 1997 Annual Report. Bethesda, MD: US Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Disease, 1997.
36. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
37. National Center for Health Statistics Health, United States, 1996. Hyattsville, MD: Public Health Service; 1997.
38. Jorge TI, Henry SS, Tai-Shing L, et al. Drug Treatment of Hypertension in the Elderly: A Meta-Analysis. Ann Intern Med. 1994;121:355-362.
39. Yusef S, Wittes J, Probstfield J. Evaluating effects of treatment in subgroups of patients within a clinical trial: The case of non-Q-wave myocardial infarction and beta-blockers. AmJ Cardiol. 1990;66:220-222.
40. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N EnglJ Med. 1992;327:685-691.
41. Pfeffer MA, Braunwald E, MoyJ LA, et al. Effect of captropril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N EnglJ Med. 1992; 327:669-677.
42. Burrell LM, Johnston CI. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular diseases (Review). Drugs Aging. 1997;10(6):421-434.
43. Tikkanen I, Omvik P, Jensen HA. Comparison of angiotensin II receptor antagonist losartan with the angiotensin converting enzyme inhibitor captopril in patients with essential hypertension J Hypertens. 1995;13(11):1343-1351.
44. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium with enalapril maleate in patients with essential hypertension. Hypertension 1995;25(6):1345-1350.
45. Pitt B, Segal R, Martinez FA. Randomized trial losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in Elderly Study, ELITE). Lancet. 1997;349(9054):747-752
46. Packer M, O'Connor CM, Ghali JK, et al for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N EnglJ Med. 1996;335:1107-1114.
47. Cohn JN, Zieche S, Smith R, et al for the Vasodilator-Heart Failure Trial. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation. 1997;96:856-863.
48. The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
49. Sowers JR, Epstein M. Diabetes mellitus and hypertension: An update. Hypertension. 1995;26(part 1):869-879.
50. Puig JG, Ruilope LM, Ortega R Antihypertensive treatment efficacy in type II diabetes mellitus. Disassociation between casual and 24-hour ambulatory blood pressure. Hypertension. 1995;26(part 2):1093-1099.
51. Jacobs DB, Sowers JR, Hmeidan A, et al. Effects of weight reduction on cellular cation metabolism and vascular resistance. Hypertension. 1993;21:308-314.
52. Adult Treatment Panel II: Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation. 1994;89:1336.
53. American Diabetes Association. American Diabetes Association: Clinical practice recommendations. Diabetes Care. 1997;20(suppl):S1-S70.
54. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
55. Curb JD, Pressel SL, Cutler JA, et al for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886-1892.
56. Shorr RI, Ray WA, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997;278:40-43.
57. Lewis EJ, Hunsicker LG, Bain RP, et al for the Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
58. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med. 1996;156:286-289.
59. Chan JC, Critchley JA, Tomlinson B, et al. Antihypertensive and anti-albumineric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without NIDDM. Am J Nephrol. 1997;17:72-80.
60. Luis MR. Renoprotection and renin-angiotensin system blockade in diabetes mellitus. Am J Hypertens. 1997;10:325S-331S.
61. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
62. Velussi M, BOTTOCO E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertension NIDDM patients Diabetes. 1996;45:216-222.
63. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652
64. Tatti P, Pahor M, Byington RP, et al. Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM) (abstr). Circulation 1997;96 (suppl I):I-764